Chapter title |
Generation and Evaluation of Prophylactic mRNA Vaccines Against Allergy.
|
---|---|
Chapter number | 7 |
Book title |
RNA Vaccines
|
Published in |
Methods in molecular biology, January 2017
|
DOI | 10.1007/978-1-4939-6481-9_7 |
Pubmed ID | |
Book ISBNs |
978-1-4939-6479-6, 978-1-4939-6481-9
|
Authors |
Richard Weiss, Sandra Scheiblhofer, Josef Thalhamer, Weiss, Richard, Scheiblhofer, Sandra, Thalhamer, Josef |
Editors |
Thomas Kramps, Knut Elbers |
Abstract |
Due to the worldwide increase in allergies and a limited efficacy of therapeutic interventions, the need for prophylactic vaccination against allergies has been recognized. mRNA and DNA vaccines have demonstrated their high potential for preventing allergic sensitization by inducing an immunological bias that prevents TH2 sensitization. However, only mRNA vaccines fulfill the stringent safety requirements for vaccination of healthy children. In this chapter, we describe the generation of conventional as well as self-replicating mRNA vaccines and methods to test their prophylactic efficacy in animal models. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 28 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 7 | 25% |
Researcher | 3 | 11% |
Student > Master | 3 | 11% |
Other | 1 | 4% |
Professor | 1 | 4% |
Other | 3 | 11% |
Unknown | 10 | 36% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 4 | 14% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 11% |
Engineering | 3 | 11% |
Veterinary Science and Veterinary Medicine | 1 | 4% |
Immunology and Microbiology | 1 | 4% |
Other | 4 | 14% |
Unknown | 12 | 43% |